OnQ Prostate is post-processing software that supports improved detection of clinically significant prostate cancer (PCa). It utilizes artificial intelligence and a patented advanced diffusion MRI technique called Restriction Spectrum Imaging (RSI) to increase the conspicuity of restricted water, a hallmark characteristic of aggressive cancer.
Product specifications Information source: Vendor
Last updated: Dec. 1, 2020
General
Product name OnQ Prostate
Company Cortechs.ai
Subspeciality Abdomen
Modality MR
Disease targeted Prostate cancer
Key-features Color fusion map, restricted signal map
Suggested use Before: stratifying reading process (non, single, double read), flagging acute findings
During: perception aid (prompting all abnormalities/results/heatmaps)
Data characteristics
Population patients at risk of prostate cancer
Input multi-shell MRI sequence, T2 weighted MRI sequence
Input format DICOM
Output Color fusion map, restricted signal map
Output format DICOM
Technology
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone webbased
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based
Trigger for analysis On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time 1 - 10 minutes
Certification
CE
No or not yet,
FDA
510(k) cleared, Class II
Market presence
On market since 12-2019
Distribution channels Nuance, Siemens
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model Pay-per-use, Subscription
Based on Number of installations, Number of analyses
Evidence
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers